Knight Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Canada · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
3400 Boul De Maisonneuve O Suite 1055, M...Phone Number
(514) 484-4483Website
www.gud-knight.comRevenue
$360 MillionStock Symbol
GUDIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Knight Therapeutics
Knight Therapeutics is a leading pan-American specialty pharmaceutical company focused on providing innovative therapies in Canada and Latin America. The company develops and commercializes a range of pharmaceutical products, including the recently launched JORNAY PM, an extended-release formulation of methylphenidate. Knight Therapeutics aims to address the unique healthcare needs of patients in these regions. Their target clients include healthcare providers and patients requiring specialized medications.Explore more
Knight Therapeutics Org Chart
JW
Global Senior Director, Head of Tax
FP
Senior Director, Finance Corporate
AM
Director, Corporate Treasury & Finance Busine...
JL
Director, Value, Access & Pricing
JE
Associate Director, Finance Fpa
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Knight Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Knight Therapeutics is spiking on competitors!
Click to see if Knight Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Knight Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Knight Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Knight Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Knight Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Knight Therapeutics
Product Launch: Get notified when Knight Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Knight Therapeutics
Compare insights from companies similar to Knight Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Knight Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Knight Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Knight Therapeutics.
Knight Therapeutics financials insights
Gather financial insights about Knight Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Multiple Rounds
$364.6M
2015
Debt
$6M
Knight Therapeutics Tech Stack
A closer look at the technologies used by Knight Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Acquisitions, Finance, Financing & Debt
Person-Based
Acquisitions, Finance, Financing & Debt
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Regulations
Person-Based
Share Placement, Finance
Knight Therapeutics News & Media
Knight Therapeutics Inc. (GUD:CA) Q3 2025 Earnings Call Transcript
Knight Therapeutics Inc. (GUD:CA) Q3 2025 Earnings Call November 6, 2025 8:30 AM ESTCompany ParticipantsSamira Sakhia - President, CEO & DirectorArvind...Knight Therapeutics Secures US$100 Million Credit Facility to Boost Growth - TipRanks.com
Knight Therapeutics ( ($TSE:GUD) ) has shared an announcement. Knight Therapeutics Inc. has successfully closed a US$100 million revolving credit facility, doubling...Knight Therapeutics Secures US$50 Million Credit Facility to Fuel Growth - TipRanks.com
Knight Therapeutics ( ($TSE:GUD) ) just unveiled an update. Knight Therapeutics Inc. has secured a US$50 million revolving credit facility with the National Bank of...Knight Therapeutics Inc. (KHTRF) Q4 2024 Earnings Call Transcript
Knight Therapeutics Inc. (OTCPK:KHTRF) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ETCompany ParticipantsSamira Sakhia - President and Chief...
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Knight Therapeutics
Sign Up For FreeTo access detailed company insights
Knight Therapeutics is a leading pan-American specialty pharmaceutical company focused on providing innovative therapies in Canada and Latin America. The company develops and commercializes a range of pharmaceutical products, including the recently launched JORNAY PM, an extended-release formulation of methylphenidate. Knight Therapeutics aims to a... Read More
